+2,028.8%
CLS vs GSK
+42.7%
+1,986.1%
-56.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.9% | -1.3% | +4.2% | +2.9% |
| 7D | +0.2% | -3.1% | +3.3% | +0.1% |
| 30D | -19.0% | -0.9% | -18.1% | -19.0% |
| 3M | -21.7% | -4.2% | -17.5% | -21.5% |
| 6M | -29.0% | -1.6% | -27.4% | -29.1% |
| YTD | -17.7% | +2.6% | -20.3% | -17.9% |
| 1Y | -18.9% | +6.2% | -25.1% | -19.3% |
| 3Y | +767.5% | +55.0% | +712.5% | +691.4% |
| 5Y | +2,028.8% | +42.8% | +1,986.0% | +1,723.8% |
| All | +2,028.8% | +42.7% | +1,986.1% | +1,723.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling